期刊文献+

地县级疾病预防控制机构乙肝防制工作落实情况及障碍分析 被引量:1

Analysis on Fulfillment and Obstacles of Prevention and Control of Hepatitis B in China Cities and Counties
下载PDF
导出
摘要 [目的]了解我国乙肝防制工作的现状,为制定政策提供科学依据。[方法]2005年7月通过回顾性调查和意向调查相结合的方法,对样本单位进行调查。[结果]按照修订的工作规范要求,我国地、县级疾病预防控制机构乙肝防制工作质量达成程度为69.98%,数量完成程度为66.94%,地级和县级差异无统计学意义;影响质量达成和数量完成情况的主要原因归结为缺乏足够的经费、缺乏足够的人力配备和缺乏相应的物资配备三方面。[结论]经费、人员和相应物资缺乏是制约乙肝防制工作的瓶颈,如果不从管理、资源配置等入手,我国乙肝防制工作将难以达到预期目标。 [Objective]To know the status quo and obstacles of HepB control and find the evidence for policy-making in the context of China.[Methods]Retrospective and intention survey.[Results]The quality of the HepB control work in China cities and counties achieved 69.98% compared by the standard of work book,and the quantity achieved 66.94%.There is no difference between sampled cities and counties.The main obstacles to control HepB are the lack of fund,staff and materials.[Conclusion]The management and resources allocation are the most important issues to perfectly control HepB.
出处 《预防医学论坛》 2006年第6期644-646,共3页 Preventive Medicine Tribune
基金 国家自然科学基金(批号:70573023) 卫生部科研基金资助项目
关键词 乙型肝炎 预防控制工作 障碍 Hepatitis B Prevention and control Obstacles
  • 相关文献

参考文献5

二级参考文献24

  • 1李敬云,鲍作义,吴晓明,田辛,张习坦,陈玲宜,王洪莉.一起戊型肝炎暴发的流行病学调查[J].解放军预防医学杂志,1996,14(3):182-184. 被引量:7
  • 2M-Y Lai.Potent HBVDNA suppression with peginterferon alpha-2a + lamivudine combination therapy reduces the development of YMDD mutants but has no effect on sustained response compared with peginterferon alpha-2a monotherapy.J Gastroenterol Hepatol, 2004, 19(suppl):A690.
  • 3Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351:1521-1531.
  • 4Abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, USA, October 29-November 2004.Hepatology,2004,40(4 Suppl 1): 193A. Abstract 70.
  • 5Abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, USA, October 29-November 2004. Hepatology,2004,40(4 Suppl 1):664A.Abstract 1152.
  • 6Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis,2004,24(Suppl1):31-36.
  • 7Cooksley WG.Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis,2004,24(Suppl1):45-53.
  • 8Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology ,2003,37:1172-1179.
  • 9Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol, 2000,33:992-997.
  • 10Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology, 2004,39:1694-1701.

共引文献50

同被引文献4

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部